Clinical trial of Δ1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer: A report of the cooperative breast cancer group
✍ Scribed by Ira S. Goldenberg
- Publisher
- John Wiley and Sons
- Year
- 1969
- Tongue
- English
- Weight
- 329 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
A'-TESTOLOLACTONE (NSC 23759), MEDROXY PROGESTERONE ACETATE (NSC 26386) AND OXYLONE ACETATE (NSC 47438) I N ADVANCED FEMALE MAMMARY CANCER A Reil,ort of the Cooperative Byeast Cancer G ~u ~I REPORT PREPARED HY IRA S. GOI-DEKHERG, MD Three hundred and nineteen women with advanced and metastatic carcinoma of t h e breast were treated according to the protocol of the Cooperative Breast Cancer G r o u p with one of three compounds: Al-testololactone, micronized medroxy progesterone acetate or oxylone acetate.* The oxylone produced 19.4% objective remissions, the progesterone 9.3% and the Al-testololactone, 4.9%. W o m e n w h o responded to therapy with a n y of these drugs had a better survival experience than those w h o did n o t since 50% of the responders were dead 21 months from the start of therapy b u t 50% of the nonresponders were dead 6 months thereafter. Although oxylone caused a moderate degree of difficulty with steroid effects, it might be considered effective therapy f o r advanced mammary cancer, especially as secondary therapy. HERAPEUTICAL.LY EFFECTIVE hfODlFICATlON T of the hormonal milieu of women with advanced mammary cancer can be achieved with many exogenous hormonal agents. However, objective and subjective improvement is often accompanied by disagreeable physiologic effects from the preparations. T h e National Cancer Institute has been working with the Cooperative Breast Cancer Group since 1957 to develop potent anticancer agents with minimal undesirable qualities and many steroids have been evaluated clinically in this program. This report deals with 3 compounds: ill-testololactone, medroxy progesterone acetate and oxylone acetate as therapy in 319 women with advanced mammary cancer.